Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives $286.72 Average Target Price from Analysts

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been assigned a consensus recommendation of “Buy” from the eighteen ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $286.7222.

Several brokerages have weighed in on JAZZ. TD Cowen upped their target price on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. increased their target price on shares of Jazz Pharmaceuticals from $265.00 to $276.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Barclays raised their target price on shares of Jazz Pharmaceuticals from $270.00 to $271.00 and gave the company an “overweight” rating in a research report on Thursday, September 10th. UBS Group boosted their price target on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a “buy” rating in a report on Friday, September 11th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $240.57 on Friday. The company has a market capitalization of $15.62 billion, a P/E ratio of 16.59, a P/E/G ratio of 0.22 and a beta of 0.36. The company’s 50-day simple moving average is $249.19 and its two-hundred day simple moving average is $226.77. Jazz Pharmaceuticals has a one year low of $125.79 and a one year high of $266.38. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. During the same period in the prior year, the firm posted ($8.25) EPS. The business’s revenue was up 15.5% on a year-over-year basis. As a group, equities analysts anticipate that Jazz Pharmaceuticals will post 21.5 EPS for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Renee D. Gala sold 2,000 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $243.03, for a total transaction of $486,060.00. Following the sale, the chief executive officer owned 143,394 shares of the company’s stock, valued at approximately $34,849,043.82. This trade represents a 1.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the sale, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. This trade represents a 2.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 98,121 shares of company stock valued at $24,443,842. 4.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. USA Financial Formulas bought a new position in Jazz Pharmaceuticals in the first quarter worth about $25,000. Ameritas Advisory Services LLC bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at about $47,000. Leonteq Securities AG bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $50,000. Westpac Banking Corp purchased a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $51,000. Finally, Root Financial Partners LLC grew its position in shares of Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock worth $56,000 after buying an additional 89 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for disorders in neuroscience and oncology. The company concentrates on conditions with significant unmet medical needs, including sleep disorders, epilepsy, rare diseases and certain cancers.

Its neuroscience portfolio includes Xywav and Xyrem, oxybate-based treatments for narcolepsy, with Xywav also indicated for idiopathic hypersomnia in adults. Jazz also markets Epidiolex in the United States, known as Epidyolex in some international markets, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

In oncology, Jazz’s products include Rylaze, an asparaginase therapy used as part of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca, used for certain patients with metastatic small cell lung cancer; and Vyxeos, a chemotherapy formulation for certain cases of newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.